Nutricosmetics Formulation Expert & Microbiome Author Joins Codex Labs Medical Advisory Board
San Jose, CA, May 22, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, and Paula Simpson, nutricosmetics formulator, author and microbiome expert, recently announced the addition of Paula to the Codex Labs medical advisory board.
“As we delve deeper into skin-gut-brain integrative wellness solutions, we are excited to find partners who are experts in functional and clinical nutrition, as well as formulation of accessible skin-gut-brain supporting supplements. Our goal is to expand our ingestibles from acne to other skin conditions, and clinically prove and publish their efficacy through research studies with our medical advisory board dermatologists,” said Dr. Barbara Paldus, Founder and CEO of Codex Labs.
"I'm thrilled to be a part of Codex Labs’ incredible team of medical, microbiome science & ethnobotany experts. With my integrated background, I hope to support Codex Labs in bringing forth unique and personalized formulations for healthy, balanced skin inside and out," stated Paula Simpson, Author & Founder of Nutribloom Consulting. “Our skin doesn't function in isolation; it has a codependent relationship with the gut and immune system. Via gut-skin axis, microbes are important contributors for healthy balanced skin. Nurturing it from the inside and out, can support and encourage those good bacteria to flourish and protect us from pathogens or stressors that have a negative effect on the health and appearance of our skin."
About Codex Labs
Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain integrative solutions that contain potent, biotech-derived plant-based actives. Our products are focused on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema and psoriasis. Our free DermSCORE self-assessment app offers consumers a data-driven, derm-approved approach for managing acne. The brand has been heralded by dermatologists for creating a new breed of effective, vegan, cruelty-free and sustainable dermo-cosmetic solutions.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Lassila & Tikanoja plc: Interim Report 1 January–31 March 202426.4.2024 07:00:00 CEST | Press release
Lassila & Tikanoja plc Stock exchange release 26 April 2024 at 8:00 a.m. Lassila & Tikanoja plc: Interim Report 1 January–31 March 2024 STABLE RESULT IN THE FINNISH DIVISIONS – FACILITY SERVICES SWEDEN DID NOT MEET EXPECTATIONS Unless otherwise mentioned, the figures in brackets refer to the corresponding period in the previous year. Net sales for the first quarter were EUR 185.0 million (192.7). Net sales decreased by 4.0%. The decline in net sales was due to the weak economic environment.Adjusted operating profit was EUR 0.0 million (1.4) and operating profit was EUR -1.7 million (1.4). Earnings per share were EUR -0.02 (0.03). Net cash flow from operating activities after investments was EUR -9.4 million (19.2) and net cash flow from operating activities after investments per share was EUR -0.25 (0.50). Net cash flow was negatively impacted by the reduction in factoring. Outlook for the year 2024 Net sales in 2024 are estimated to be at the same level as in the previous year, and op
Hexatronic Group AB (publ) Interim report January – March 202426.4.2024 07:00:00 CEST | Press release
Hexatronic Group AB (publ) Interim report January – March 2024 Continued strong operating cash flow and contribution from new focus areas First quarter (January 1 – March 31, 2024) Net sales decreased by 16 percent to MSEK 1,782 (2,115). Sales decreased organically by 27 percent.EBITA decreased by 54 percent to MSEK 168 (365), corresponding to an EBITA margin of 9.4 percent (17.2).Operating profit (EBIT) decreased by 59 percent to MSEK 138 (340), corresponding to an operating margin of 7.7 percent (16.1).Net profit decreased by 73 percent to MSEK 61 (224).Earnings per share after dilution amounted to SEK 0.31 (1.09).Leverage ratio (net debt/EBITDA (pro forma), R12) amounted to 2.0x compared to 1.7x as of December 31, 2023.Cash flow from operating activities amounted to MSEK 270 (28). Significant events during the quarter The Board of Directors proposes to the Annual General Meeting that no payment of dividend will be made for the financial year 2023.Hexatronic merges its two Swedish wh
IMCD reports EBITA of EUR 127 million in the first three months of 202426.4.2024 07:00:00 CEST | Press release
Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTS Gross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023)Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis)Free cash flow of EUR 106 million (first three months of 2023: EUR 147 million)Cash earnings per share decline of 19% to EUR 1.41 (first three months of 2023: EUR 1.74)Successful completion of six acquisitions: Valuetree and CJ Shah in India, Joli Foods in Colombia, RBD in China, Euro Chemo-Pharma/Biofresh in Malaysia and Gova in the Benelux Valerie Diele-Braun, CEO: "In a volatile first quarter of the year, we faced challenging conditions in some of our market segments, resulting in a lower operating EBITA of EUR 127 million versus a very strong Q1 2023. Whilst our ac
Kitron: Ex dividend NOK 0.75 today26.4.2024 07:00:00 CEST | Press release
The shares in Kitron ASA will be traded ex dividend NOK 0.75 as from today, 26.04.2024. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Signify reports first quarter sales of EUR 1.5 billion, operational profitability of 8.3% and a free cash flow of EUR 80 million26.4.2024 07:00:00 CEST | Press release
Press Release April 26, 2024 Signify reports first quarter sales of EUR 1.5 billion, operational profitability of 8.3% and a free cash flow of EUR 80 million First quarter 20241 Signify's installed base of connected light points increased from 124 million in Q4 23 to 126 million in Q1 24Achieved reasonable assurance on full Brighter Lives, Better World 2025 program, including scope 3 emissionsSales of EUR 1,468 million; nominal sales decline of -12.5% and CSG of -10.1%LED-based sales represented 87% of total sales (Q1 23: 82%)Adj. EBITA margin of 8.3% (Q1 23: 8.9%)Net income of EUR 44 million (Q1 23: EUR 28 million)Free cash flow of EUR 80 million (Q1 23: EUR 51 million) Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s first quarter 2024 results. “In the first quarter, we saw improving dynamics in our US Professional, OEM and Consumer businesses, while the market in China remained soft and the European Professional busi